Serum copeptin levels in predicting nondippers in newly diagnosed hypertension

Blood Pressure Monitoring

Volumn 20, Issue 4, 2015, Pages 199-203

  Uzun, Fatih ^a   Biyik, Ismail ^b   Akturk, Ibrahim F ^a   Yalcin, Ahmet A ^a   Erturk, Mehmet ^a   Oner, Ender ^a   Kalkan, Ali K ^a   Yalcin, Burce ^a   Atmaca, Husnu ^c  

^a MEHMET AKIF ERSOY THORACIC AND CARDIOVASCULAR SURGERY TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Usak State Hospital   (Turkey)

^c Ordu State Hospital   (Turkey)

Author keywords

arginine vasopressin; copeptin; dipper; hypertension; nondipper

Indexed keywords

COPEPTIN; GLYCOPEPTIDE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD SAMPLING; BODY MASS; CIRCADIAN RHYTHM; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIPPER HYPERTENSION; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONDIPPER HYPERTENSION; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SMOKING; SYSTOLIC BLOOD PRESSURE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; PATHOPHYSIOLOGY;

ADULT; BLOOD PRESSURE; FEMALE; GLYCOPEPTIDES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED;

EID: 84937780338     PISSN: 13595237     EISSN: 14735725     Source Type: Journal    
DOI: 10.1097/MBP.0000000000000123     Document Type: Article

References (29)

1. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2224-2260
2. Makridakis S, DiNicolantonio JJ. Hypertension: empirical evidence and implications in 2014. Open Heart 2014; 1: e000048
3. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572
4. Brotman DJ, Davidson MB, Boumitri M, Vidt DG. Impaired diurnal blood pressure variation and all-cause mortality. Am J Hypertens 2008; 21: 92-97
5. Kohara K, Nishida W, Maguchi M, Hiwada K. Autonomic nervous function in non-dipper essential hypertensive subjects. Evaluation by power spectral analysis of heart rate variability. Hypertension 1995; 26: 808-814
6. Munakata M, Imai Y, Abe K, Sasaki S, Minami N, Sekino H, Yoshinaga K. Involvement of the hypothalamo-pituitary-Adrenal axis in the control of circadian blood pressure rhythm. J Hypertens Suppl 1988; 6: S44-S46
7. Dunser MW, Wenzel V, Mayr AJ, Hasibeder WR. Management of vasodilatory shock: defining the role of arginine vasopressin. Drugs 2003; 63: 237-256
8. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 2 - clinical physiology. Crit Care 2004; 8: 15-23
9. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1 - receptor physiology. Crit Care 2003; 7: 427-434
10. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112-119
11. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Muller B, Keller U, Christ-Crain M. Changes in plasma copeptin, the C-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007; 92: 3973-3978
12. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 34: 2159-2219
13. Verdecchia P, Porcellati C, Schillaci G, Borgioni C, Ciucci A, Battistelli M, et al. Ambulatory blood pressure. An independent predictor of prognosis in essential hypertension. Hypertension 1994; 24: 793-801
14. Tenderenda-Banasiuk E, Wasilewska A, Filonowicz R, Jakubowska U, Waszkiewicz-Stojda M. Serum copeptin levels in adolescents with primary hypertension. Pediatr Nephrol 2014; 29: 423-429
15. Zheng X, Zhang T, Ding H, Wang C. Plasma levels of beta-endorphin, leucine enkephalin and arginine vasopressin in patients with essential hypertension and the effects of clonidine. Int J Cardiol 1995; 51: 233-244
16. Littlejohn NK, Siel RB Jr, Ketsawatsomkron P, Pelham CJ, Pearson NA, Hilzendeger AM, et al. Hypertension in mice with transgenic activation of the brain renin-Angiotensin system is vasopressin dependent. Am J Physiol Regul Integr Comp Physiol 2013; 304: R818-R828
17. Aoyagi T, Koshimizu TA, Tanoue A. Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice. Kidney Int 2009; 76: 1035-1039
18. Nickel NP, Lichtinghagen R, Golpon H, Olsson KM, Brand K, Welte T, Hoeper MM. Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension. Respir Res 2013; 14: 130
19. Uzu T, Ishikawa K, Fujii T, Nakamura S, Inenaga T, Kimura G. Sodium restriction shifts circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1997; 96: 1859-1862
20. Bartelstone HJ, Nasmyth PA. Vasopressin potentiation of catecholamine actions in dog, rat, cat, and rat aortic strip. Am J Physiol 1965; 208: 754-762
21. Uzu T, Kimura G. Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635-1638
22. Elisaf M, Pappas H, Kalaitzidis R, Katopodis K, Theodorou J, Siamopoulos KG. Ambulatory blood pressure monitoring in hemodialysis patients. J Hum Hypertens 1996; 10: S43-S47
23. Huang Y, Mai W, Hu Y, Wu Y, Song Y, Qiu R, et al. Poor sleep quality, stress status, and sympathetic nervous system activation in nondipping hypertension. Blood Press Monit 2011; 16: 117-123
24. Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008; 29: 341-346
25. Yalta K, Sivri N, Yalta T, Geyik B, Aksoy Y, Yetkin E. Copeptin (C-terminal provasopressin). a promising marker of arrhythmogenesis in arrhythmia prone subjects?. Int J Cardiol 2011; 148: 105
26. Chatterjee K. Neurohormonal activation in congestive heart failure and the role of vasopressin. Am J Cardiol 2005; 95 (9A): 8B-13B.
27. Satoh M, Kikuya M, Ohkubo T, Mori T, Metoki H, Hashimoto T, et al. Aldosterone-to-renin ratio and nocturnal blood pressure decline in a general population: the Ohasama study. J Hypertens 2011; 29: 1940-1947
28. Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013; 167: 1750-1759
29. Riphagen IJ, Boertien WE, Alkhalaf A, Kleefstra N, Gansevoort RT, Groenier KH, et al. Copeptin, a surrogate marker for arginine vasopressin, is associated with cardiovascular and all-cause mortality in patients with type 2 diabetes (ZODIAC-31). Diabetes Care 2013; 36: 3201-3207